Novartis Q4 Results
↓
Content
Click below to navigate
through the document
... and in 2023, met/exceeded our upgraded FY guidance
↑
Company overview
Financial review
Continuing operations¹
In cc
Conclusions
FINANCIAL PROFILE
Appendix
References
FY guidance (Q3
earnings Oct 2023)
Actual results
FY 2023 vs. PY
Prior guidance
before upgrades
(Q4 2022)
Sales expected to grow high
single-digit
+10%
Guidance as per Q4 2022 earnings
Sales expected to grow low to mid single-digit
Core operating income expected
to grow mid to high-teens
+18%
Guidance as per Q4 2022 earnings
Core operating income expected to grow
mid to high single-digit
1. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities. Constant currencies (cc),
core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
26View entire presentation